Sanofi and Regeneron’s Dupixent Meets All Endpoints in P-III Study in Children with Atopic Dermatitis

August 30, 2021 Auto Bot Atopic Dermatitis, Children, Clinical Trials, Dupixent, Regeneron, Sanofi 0

Shots:

  • The P-II/III LIBERTY AD PRESCHOOL (part B) involves assessing the efficacy & safety of Dupixent (200/300mg) + low-potency TCS vs TCS alone in 162 children aged 6mos. to 5 years with uncontrolled mod. to sev. AD
  • Result: clear or almost-clear skin (28% vs 4%); 75% or greater overall disease improvement (53% vs 11%); improvement in EASI & itch (70% & 49% vs 20% & 2%); 50% reduction in skin infection (12% vs 24%); 70% reduction in total number of infections; improvement in health related QoL measures @16wks.
  • The results reinforce the well-established safety profile of Dupixent as the first ever biologic medicine for AD currently approved for patients as young 6yrs. old

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: France 24

The post Sanofi and Regeneron’s Dupixent Meets All Endpoints in P-III Study in Children with Atopic Dermatitis first appeared on PharmaShots.